Depression is one of the most prevalent and treatment-resistant conditions globally — approximately one-third of patients fail to achieve remission with first-line antidepressants. Research peptides represent mechanistically novel approaches that, for some presentations, address aspects of the biology of depression that SSRIs and SNRIs do not. This review covers the strongest candidates — Semax, Selank, BPC-157, and DSIP — with honest assessment of evidence levels, which remain primarily preclinical or from small human studies.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
There is insufficient clinical data to make a definitive recommendation. Semax has the most direct BDNF-driven mechanism relevant to treatment resistance (where antidepressants often fail because they don't adequately restore BDNF/neuroplasticity). BPC-157 addresses the most mechanisms simultaneously.
Semax: BDNF and the Neuroplasticity Model
The "neurotrophic hypothesis" of depression proposes that reduced BDNF (brain-derived neurotrophic factor) in key limbic structures — particularly the hippocampus — is a central pathological mechanism. All major antidepressants, including SSRIs, increase BDNF expression with chronic use; this neuroplasticity restoration may underlie their therapeutic effects rather than simple monoamine modulation.
Semax is among the most potent non-invasive BDNF-upregulating compounds available for research, producing significant BDNF elevation within hours of intranasal administration. In Russian clinical data, Semax showed antidepressant effects in patients with cognitive-deficit depression and depression following stroke or brain injury. Its mood-brightening, motivation-improving effects reported consistently in community use are consistent with its BDNF and dopaminergic mechanism. For depression characterised by low motivation, cognitive blunting, and anhedonia (common in so-called "flat" depression or atypical depression), Semax's profile is mechanistically appealing.
Selank: Anxiety-Depression Comorbidity
Mixed anxiety-depression is the most common depression presentation clinically. Selank's dual anxiolytic and mood-stabilising properties, derived from its GABA-A modulation and enkephalin stabilisation, directly address this comorbidity. Russian clinical trials showed Selank effective for "asthenic" presentations — depression with prominent fatigue, emotional exhaustion, and anxiety — that are common but often poorly addressed by SSRIs (which can worsen anxiety initially).
Selank also has serotonergic modulatory effects, providing a plausible antidepressant mechanism beyond GABA. For the anxious-depressive presentation that represents a large portion of treatment-seeking patients, Selank's combination of GABAergic anxiolysis and serotonergic modulation without the activation-anxiety of SSRIs represents a distinct mechanistic option.
BPC-157: Dopamine, Serotonin, and the Gut-Brain Axis
BPC-157 has the most multi-system relevance for depression. Its effects include: dopaminergic protection and sensitivity normalisation (relevant for anhedonic/reward-deficit depression), serotonergic modulation (behavioural studies show antidepressant-like effects in standard forced swim and tail suspension paradigms), HPA axis normalisation (reducing pathological cortisol elevation in chronic stress models), and gastrointestinal health improvement (relevant via the gut-brain axis — gut dysbiosis contributes to depression through inflammatory and neurotransmitter-mediated pathways).
BPC-157 has shown reversal of both serotonergic and dopaminergic depression models in rodents. The breadth of its antidepressant-relevant mechanisms — covering dopamine, serotonin, cortisol, and gut health simultaneously — makes it an unusually broad-spectrum adjunct for depression research, though human clinical trial data specifically for depression is lacking.
DSIP: Cortisol and Sleep Architecture
Delta Sleep-Inducing Peptide (DSIP) addresses two core biological abnormalities of depression: HPA axis dysregulation (elevated cortisol, flattened diurnal cortisol rhythm) and sleep architecture disruption (reduced slow-wave sleep, altered REM distribution). DSIP directly reduces ACTH and normalises cortisol patterns, while improving slow-wave sleep continuity. Given that sleep disruption and HPA dysregulation are both upstream causes and downstream consequences of depression, DSIP's effects on these systems have genuine antidepressant rationale.
DSIP is less known and less available than Semax or Selank, but for depression with prominent HPA dysregulation or sleep disruption — particularly post-traumatic, burnout-related, or melancholic presentations — it represents a mechanistically specific option.
Peptides for Depression — Profile Summary
| Peptide | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Semax | 200–600 mcg | Intranasal | BDNF, dopamine — motivation/anhedonia | Best for cognitive-deficit/anhedonic depression |
| Selank | 250–500 mcg | Intranasal | GABA, serotonin — anxiety-depression | Best for anxious-depressive comorbidity |
| BPC-157 | 250–500 mcg | SubQ or oral | Dopamine, serotonin, gut-brain, HPA | Broad-spectrum adjunct; systemic mechanism |
| DSIP | 100–300 mcg | SubQ | HPA axis, sleep architecture | Best for HPA dysregulation / melancholic type |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Research peptides should not be used as replacements for established antidepressant therapy without medical supervision. They have not been validated in large human clinical trials for depression to the standard required for antidepressant approval. For individuals who have tried conventional treatments and found them insufficient, research peptides may be appropriate adjuncts, but this decision should involve a physician — particularly given interactions between peptide mechanisms and existing medications.
There is insufficient clinical data to make a definitive recommendation. Semax has the most direct BDNF-driven mechanism relevant to treatment resistance (where antidepressants often fail because they don't adequately restore BDNF/neuroplasticity). BPC-157 addresses the most mechanisms simultaneously. For treatment-resistant cases, a clinical evaluation for underlying hormonal, inflammatory, or gut-health contributions to depression is equally important.
The primary concern with combining serotonergic peptides (Semax, Selank have serotonergic components) with SSRIs is theoretical risk of serotonin syndrome. In practice, this risk appears low given the indirect serotonergic effects of these peptides, but it is not well-studied. BPC-157 has direct protective effects on serotonergic neurons in animal models and is mechanistically unlikely to cause serotonin syndrome. Consulting a physician before adding peptides to an existing SSRI regimen is recommended.
This may be the most appropriate use case for peptide research in depression. Burnout-related and chronic stress-induced depression involves the same BPC-157, DSIP, and Selank mechanisms most directly: HPA dysregulation, dopaminergic blunting, sleep disruption, and anxiety-depression comorbidity. The literature on stress-induced animal depression models consistently shows positive effects for these compounds.